Clinical Trial Update: To Evaluate the Tolerability, Pharmacokinetics, and Pharmacodynamics of IMM-H014 in Patients With MASH [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial update for IMM-H014 to assess tolerability, pharmacokinetics, and pharmacodynamics in patients with Metabolic Dysfunction-Associated …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Metabolic Dysfunction-associated Steatohepatitis

Drugs mentioned

• IMM-H014

Snippet

Sponsor: Changchun Intellicrown Pharmaceutical Co. LTD | Conditions: Metabolic Dysfunction-Associated Steatohepatitis (MASH) | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING